Early Drug Development Group
Our preclinical and clinical operation structures rely on an interdisciplinary group of medical oncologists, pharmacologists and molecular biology experts with extensive experience in preclinical studies and clinical trials. We are capable of offering professional services covering all stages of your R&D program, to establish an attractive route to the clinic in a fast, efficient and cost effective manner.
Optimize, Innovate, Collaborate
We support medtech and biotech start-ups, pharmaceutical companies, investment fund groups and academic organizations in oncology to foster their R&D programs in a time- and cost-effective manner.
Assistance on preclinical, pharmacological and CMC approaches, regulatory strategies and Phase I clinical trials in oncology.
Broad capabilities in preclinical, pharmacokinetic and radiopharmacology studies to guide clinical development.
Advice on the reliability and feasibility of reported preclinical and clinical data.
Management and execution of an efficient R&D program in oncology.
Our strength relies on an interdisciplinary team of medical oncologists, pharmacologists and molecular biology experts with unparalleled experience in non-clinical and clinical trial studies.
We are interdisciplinary research group of medical oncologists, pharmacologists and molecular biology experts. We have performed several drug development programs with more than 20 companies -ranging from small biotech to the largest pharma companies- for the evaluation of over 20 different leads (at least 8 first-in-man) in oncology, covering both small molecules and monoclonal antibodies. Over the last years, we have established a long-standing network of trusted partner companies and world-class investigators experienced in early drug development and cancer research in oncology and immunology. This enable us to offer an attractive route to the clinic optimized in terms of time and costs.
E2DG announces two posters at the 2022 AACR Annual Meeting in New Orleans highlighting our commitment to oncology innovation and our passion to build novel therapeutic strategies for cancer. For further information, click here.
Meet us digitally at #BioEurope from Oct 25-28, 2021! To learn more about us and discuss a future partnership, please feel free to connect with us via the partnering platform. For further information, click here.
Our 2021’s publications
October, 2021. Don't miss the opportunity to read some of our 2021’s publications. Congratulations to all the team! Follow this link.
A personal passion to make a difference in cancer therapy
December, 2020. Our CSO, Eugenia Riveiro has been interviewed by Science me Up about her career journey and our passion to build novel therapeutic strategies in cancer. Follow this link.
WANT TO LEARN MORE?
We look forward to learning about your specific needs, please contact us.